Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab in Incurable Platinum-Refractory Germ Cell Tumors
NCT02499952Phase 2Terminated
- Start
- Jan 2016
- Primary completion
- Jan 2017
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in germ cell tumor (GCT). Started Jan 2016; status: terminated.
02
Drugs
03
Conditions
germ cell tumor (GCT)
Beyond the preview
Go deeper on NCT02499952.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02499952.